IMPROVED ADHERENCE AND SATISFACTION
Why aren’t patients with glaucoma or ocular hypertension taking their eye drops as prescribed?
In a study that examined non-adherence rates and assessed therapy experience among glaucoma patients, 201 participants recruited from a German university completed a 16-item questionnaire about current and previous medications and non-adherence. Non-adherence was described as missing 5% or more of prescribed IOP-lowering eye drop doses.1 The level of evidence presented is not as rigorous as controlled clinical trials, and the data should be interpreted cautiously.
PATIENTS WERE SATISFIED OR VERY SATISFIED WITH PRESERVATIVE-FREE LATANOPROST
95%
of patients were satisfied (55%) or very satisfied (40%) with preservative-free latanoprost, regarding tolerability2,3
97%
(n=434)
of treatment-naive patients were satisfied (50%) or very satisfied (47%) with preservative-free latanoprost2,3
In a real-world study of 1,872 patients who switched to preservative-free latanoprost ophthalmic solution 0.005% formulation, the most common reason for switching was local intolerance or lack of efficacy of their prior treatment.2
SATISFACTION, TOLERABILITY LINKED TO ADHERENCE
In a real-world study involving 1,872 patients who switched to preservative-free latanoprost ophthalmic solution 0.005% and were treated for three months, VAS scores for treatment tolerance improved, with the degree of improvement varying based on the type of preserved treatment previously used.2
In a study that examined non-adherence rates and assessed therapy experience among glaucoma patients, 201 participants recruited from a German university completed a 16-item questionnaire about current and previous medications and non-adherence. Non-adherence was described as missing 5% or more of prescribed IOP-lowering eye drop doses.1 The level of evidence presented is not as rigorous as controlled clinical trials, and the data should be interpreted cautiously.
♠ The results of this study should be considered in the context of the limitations of this type of evidence. While these findings provide insights into the real-world performance of IYUZEH, they may not be directly comparable to results from clinical trials.
Isaac used IOP-lowering eye drops for many years and began skipping doses to avoid the side effects that came with treatment. He learned about IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free latanoprost, and asked his eye care professional about it.
With a switch to IYUZEH, Isaac looks forward to a treatment experience that’s satisfying enough to stick with long term.
†Patient portrayal. Not an actual patient.
